Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01098838 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of LCL161 in Patients With Solid Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT01098838 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 71 participants.
The verdict
NCT01098838, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
The study will evaluate the safety of increasing doses of oral LCL161 in patients with solid tumors. It is primarily designed to evaluate the side effects and find the maximum tolerated dose of LCL161.
Interventions
- DRUG LCL161
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01098838
The ClinicalTrials.gov registry entry for NCT01098838 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LCL161 is the first listed.
NCT01098838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01098838 about?
NCT01098838 is a clinical study titled "Safety and Efficacy of LCL161 in Patients With Solid Tumors". The study will evaluate the safety of increasing doses of oral LCL161 in patients with solid tumors. It is primarily designed to evaluate the side effects and find the maximum tolerated dose of LCL161.
What is the current status of trial NCT01098838?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2008-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01098838?
The interventions under investigation include: LCL161 (DRUG).
Who is sponsoring clinical trial NCT01098838?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.